Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent

Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2001, Pages 305-315

  Campiani, G ^a   Aiello, F ^b   Fabbrini, M ^b   Morelli, E ^d   Ramunno, A ^a   Armaroli, S ^b   Nacci, V ^b   Garofalo, A ^c   Greco, G ^d   Novellino, E ^d   Maga, G ^e   Spadari, S ^e   Bergamini, A ^f   Ventura, L ^f   Bongiovanni, B ^f   Capozzi, M ^f   Bolacchi, F ^f   Marini, S ^f   Coletta, M ^f   Guiso, G ^g   Caccia, S ^g   more..

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e CNR   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ENZYME INHIBITOR; NEVIRAPINE; QUINOXALINYLETHYLPYRIDYLTHIOUREA DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TROVIRDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE; DIDANOSINE; DRUG SYNERGISM; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICE; MODELS, MOLECULAR; PYRIDINES; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA; ZIDOVUDINE;

EID: 0035254261     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0010365     Document Type: Article

References (50)

1. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome
2. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)
3. Antiretroviral therapy: Reverse transcriptase inhibition
4. Antiviral therapy in human immunodeficiency virus infections
5. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
6. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4] benzodiazepin-2(1H)-one (TIBO) derivatives
7. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones
8. Characterization of the binding site of nevirapine (BI-RG-587), a non-nucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase
9. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones
10. Phenetylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogues
11. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
12. Phenetylthiazolethiourea (PETT) compounds, as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogues
13. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues
14. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: Novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity
15. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: Further structure-activity relationship studies and Identification of more Potent broad-spectrum HIV-1 RT inhibitors with antiviral activity
16. Non-nucleoside HIV-1 reverse transcriptase inhibitors: Synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents
17. 3 receptor agonists based on a pyrroloquinoxaline structure
18. 3 receptor agonists. Synthesis, further structure-activity relationships, and biological studies
19. Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2a]quinoxalinones and imidazo[1,5-a]quinoxalinones, and their aza analogues
20. 3 receptors. 2. Synthesis and biological evaluation of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines
21. Synthesis and excitatory amino acids pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones
22. A palladium-catalyzed route to huperzine A and its analogues and their acetylcholinesterase activity
23. Synthesis of amides: An efficient and chemoselective method for the preparation of β-Lactam derivatives related to HLE inhibitors
24. High-resolution structures of HIV-RT from four RT-Inhibitor complexes
25. Validation of the general purpose tripos 5.2 force field
26. Evidence of a butterfly-like configuration of structurally diverse allosteric inhibitors of the HIV-1 reverse transcriptase
27. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
28. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndrome
29. Early penetration of the blood-brain barrier by HIV
30. HIV-1, the brain, and combination therapy
31. Relationship of octanol/water partition coefficient and molecular weight to rat brain permeability
32. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides
33. The protein data bank: A computer based archival file for macromolecular structures
34. Iterative partial equalization of orbital electronegativity
35. A brief review and table of semiempirical parameters used in the hückel molecular orbital method
36. A broyden-fletcher-goldfarb-shanno optimization procedure for molecular geometries
37. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions
38. New soluble-formazan assay for HIV-1 cytopathic effects: Application of high-flux screening of synthetic and natural products for AIDS-antiviral activity
39. Inhibition of human immunodeficiency virus (HIV-1/HTLV//III//Ba-1) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides
40. Trans-acting transcriptional activation of the long terminal repeat of human t-lymphotropic viruses in infected cells
41. Detection, isolation and continuos production of cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS
42. The role of mononuclear phagocytes in HTLV-III/LAV infection
43. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche
44. A tetrazolium-based colorimetric assay for quantification of HIV-1-induced cytopathogenicity in monocyte-macrophages exposed to macrophage-colony stimulating factor
45. Rapid and automated tetrazolium based colorimetric assay for the detection of anti-HIV compounds
46. Derivation and properties of micaelis-menten type and hill type equations for reference ligands
47. A Miniaturized cell-mediated cytotoxicity assay with human effector mononuclear cells
48. Quantitative analysis of dose - Effect relationships: The combined effects of multiple drugs or enzyme inhibitors